Categories AlphaGraphs, Earnings, Technology
Key highlights from Adobe’s (ADBE) Q4 2025 earnings results
Adobe (NASDAQ: ADBE) reported revenue of $6.19 billion for the fourth quarter of 2025, up 10% year-over-year on a reported basis and in constant currency.
GAAP net income was $1.86 billion, or $4.45 per share, compared to $1.68 billion, or $3.79 per share, last year. Adjusted EPS was $5.50.
Digital Media segment revenue totaled $4.62 billion, up 11% YoY, while Digital Experience segment revenue was $1.52 billion, up 9% YoY.
Total Customer Group subscription revenue was $5.96 billion which represents a 12% growth from last year. Business Professionals & Consumers subscription revenue was $1.72 billion, up 15% YoY, and Creative & Marketing Professionals subscription revenue was $4.25 billion, up 11% YoY.
For the first quarter of 2026, Adobe expects total revenue of $6.25-6.30 billion and adjusted EPS of $5.85-5.90. For the full year of 2026, the company expects total revenue of $25.90-26.10 billion and adjusted EPS of $23.30-23.50.
Prior performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
After a rollercoaster year, is Tesla (TSLA) stock a good bet?
In recent years, Tesla's (NASDAQ: TSLA) stock has often swung between record highs and sharp corrections, reflecting shifts in investor sentiment, broader economic conditions, and changes in its financial performance.
Dollar Tree (DLTR), Dollar General (DG): Discount stores remain key gainers in a value-conscious landscape
Discount retailers Dollar Tree, Inc. (NASDAQ: DLTR) and Dollar General Corporation (NYSE: DG) have seen their stocks gain more than 30% in the past three months. The dollar stores continue
Everything you need to know about Aktis Oncology’s upcoming IPO
IPO activity in 2025 showed a marked rebound, led by the technology and healthcare sectors, after last year's sluggish performance. Aktis Oncology, which develops radiopharmaceuticals for solid tumors, is the
